Myriad Genetics INC 8-K filings
NASDAQ
Myriad Genetics announced a 12% year-over-year revenue increase in the first quarter of 2024, driven by growth in prenatal, pharmacogenomics, and hereditary cancer testing.
NASDAQ
Myriad Genetics announced an 11% year-over-year revenue increase for both the fourth quarter and full-year 2023, alongside a raised revenue guidance for 2024.
NASDAQ
Myriad Genetics reaffirmed its fiscal year 2023 revenue and non-GAAP guidance, projecting positive adjusted operating cash flow in Q4 2023, and provided preliminary Q4 2023 financial results.